Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ForteBio Inc.

www.fortebio.com

Latest From ForteBio Inc.

Ascletis Raises Mammoth $100 Million To Deploy Its US-China Hybrid Model

In the latest and most ambitious attempt to create a new global pharma with one foot in China and one in the West, Ascletis Inc. has launched with a hybrid drug development model that has attracted $100 million in committed funding.
BioPharmaceutical China

Medtech Venture Investing 2010: Do the Right Thing

In March 2010, Elsevier Business Intelligence convened a panel of venture capitalists and CEOs of devicestart-ups to discuss the climate for early and late stage funding. Their conclusion: there is money out there, if companies do the right things.

Investing In China: Views from Windhover's PharmAsia Summit

A recap of the first annual PharmAsia Summit, outlining current views on the opportunities and risks associated with investing in China.
BioPharmaceutical Middle East and Africa

Medical Device and In Vitro Diagnostics/Research Deal Statistics Quarterly, Q3 2008

Highlights from the Q3 2008 review of device and diagnostics dealmaking: Led by late-stage rounds, financing for medical device firms--at just over $1bn--showed a slight improvement over the last quarter. IPOs and follow-ons were noticeably absent in Q3, reminiscent of a time in 2003 when the IPO window closed. Not even one of the 13 device M&A transactions reached the billion-dollar mark, but the largest deal, GE Healthcare's buy of Vital Signs for $990mm, came close. In vitro diagnostics/research financings doubled to $643mm led by Illumina's $343mm FOPO. M&A activity in this industry was scant with a mere three transactions. However, Nanogen's reverse merger with Elitech Group--worth $99mm-beat the median M&A deal price ($60mm) over the past five years. Interestingly many in vitro diagnostics players turned to alliances with tech transfer entities in hopes of filling their pipelines.
BioPharmaceutical Medical Device
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Research, Analytical Equipment & Supplies
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Aria Biosystems Corp.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • ForteBio Inc.
  • Senior Management
  • Joseph D Keegan, Pres. & CEO
    Christopher M Silva, VP, Mktg.
    Terry Sayler, VP, Sales
  • Contact Info
  • ForteBio Inc.
    Phone: (650) 322-1360
    1360 Willow Rd.
    Ste. 201
    Menlo Park, CA 94025-1516
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register